Search - tctmd.com

Displaying 81 - 100 of 307

Sort: Relevancy | Date

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

Presentation ACC 2024

Main Results From The Step-hfpef Dm Trial

Presenter: Mikhail Kosiborod

April 06, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Daily News

Cognitive Impairment a Real Concern in HF Patients: HFSA

Caitlin E. Cox

March 13, 2024

News Daily News

How Meaningful Are Heart Failure Hospitalizations in Today’s RCTs?

Caitlin E. Cox

March 07, 2024

News Daily News

Semaglutide Winning Streak Continues in CKD With FLOW

Shelley Wood

March 06, 2024

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

News Daily News

Living Near Bars, Restaurants Linked to Greater Likelihood of HF

L.A. McKeown

February 29, 2024

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

L.A. McKeown

February 01, 2024

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

L.A. McKeown

January 01, 2024

News Opinion Editor's Corner

The Biggest News of 2023: TCTMD’s Top 10

Shelley Wood

January 01, 2024

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

Todd Neale

December 22, 2023

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

Shelley Wood

December 19, 2023

News Opinion CV Team Dispatch

December 2023 Dispatch for the CV Team

L.A. McKeown

December 01, 2023

News Conference News PCR London Valves 2023

EuroSMR Score Outperforms Other Tools for M-TEER Risk Profiling

Shelley Wood

November 28, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

Presentation TCT 2023

TCT 491: Diabetes mellitus as an independent risk for death and stroke in hypertrophic cardiomyopathy

Presenter: Said hajouli

October 26, 2023

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

Todd Neale

October 11, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

Advertisement

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Main Results From The Step-hfpef Dm Trial

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 2024 Dispatch for the CV Team

Cognitive Impairment a Real Concern in HF Patients: HFSA

How Meaningful Are Heart Failure Hospitalizations in Today’s RCTs?

Semaglutide Winning Streak Continues in CKD With FLOW

Debating the Role of T-TEER in the Sickest Patients

Living Near Bars, Restaurants Linked to Greater Likelihood of HF

February 2024 Dispatch for the CV Team

January 2024 Dispatch for the CV Team

The Biggest News of 2023: TCTMD’s Top 10

AHA Selects 2023’s Leading Cardiovascular Research

Who Benefits Most From Semaglutide and How Long Will That Take?

December 2023 Dispatch for the CV Team

EuroSMR Score Outperforms Other Tools for M-TEER Risk Profiling

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

TCT 491: Diabetes mellitus as an independent risk for death and stroke in hypertrophic cardiomyopathy

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 2023 News Roundup

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content